IBKS No2 SPAC (204840) - Cash Flow Conversion Efficiency

Latest as of June 2026: 0.053x

Based on the latest financial reports, IBKS No2 SPAC (204840) has a cash flow conversion efficiency ratio of 0.053x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.06 Billion ≈ $718.61K USD) by net assets (₩19.89 Billion ≈ $13.48 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of IBKS No2 SPAC for the company's overall valuation and market capitalisation.

IBKS No2 SPAC - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how IBKS No2 SPAC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 204840 share price today for real-time trading data and today's change.

IBKS No2 SPAC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of IBKS No2 SPAC ranked by their cash flow conversion efficiency. Review how much free cash does IBKS No2 SPAC generate to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
Tevogen Bio Holdings Inc. NASDAQ:TVGN	0.338x
Sunzen Biotech Bhd KLSE:0148	0.025x
Fernheizwerk Neukölln Aktiengesellschaft F:FHW	N/A
Krynica Vitamin SA WAR:KVT	0.004x
Global Knafaim Leasing Ltd TA:GKL	0.027x
I-Hwa Industrial Co Ltd TW:1456	-0.042x
BII Railway Transportation Technology Holdings Company Limited F:CN6	-0.008x
Medicamen Biotech Limited NSE:MEDICAMEQ	-0.045x

Annual Cash Flow Conversion Efficiency for IBKS No2 SPAC (2015–2025)

The table below shows the annual cash flow conversion efficiency of IBKS No2 SPAC from 2015 to 2025. Also see IBKS No2 SPAC balance sheet assets for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩19.92 Billion ≈ $13.50 Million	₩-1.12 Billion ≈ $-761.78K	-0.056x	+76.12%
2024-12-31	₩19.67 Billion ≈ $13.33 Million	₩-4.65 Billion ≈ $-3.15 Million	-0.236x	+22.80%
2023-12-31	₩12.28 Billion ≈ $8.32 Million	₩-3.76 Billion ≈ $-2.55 Million	-0.306x	-288.18%
2022-12-31	₩16.09 Billion ≈ $10.90 Million	₩-1.27 Billion ≈ $-859.85K	-0.079x	+41.51%
2021-12-31	₩16.85 Billion ≈ $11.42 Million	₩-2.27 Billion ≈ $-1.54 Million	-0.135x	+27.62%
2020-12-31	₩14.31 Billion ≈ $9.70 Million	₩-2.67 Billion ≈ $-1.81 Million	-0.186x	+58.96%
2019-12-31	₩2.36 Billion ≈ $1.60 Million	₩-1.07 Billion ≈ $-726.36K	-0.454x	+6.69%
2018-12-31	₩7.82 Billion ≈ $5.30 Million	₩-3.80 Billion ≈ $-2.58 Million	-0.486x	+24.43%
2017-12-31	₩5.94 Billion ≈ $4.02 Million	₩-3.82 Billion ≈ $-2.59 Million	-0.644x	-38.10%
2016-12-31	₩8.57 Billion ≈ $5.81 Million	₩-3.99 Billion ≈ $-2.71 Million	-0.466x	-161.72%
2015-12-31	₩3.18 Billion ≈ $2.16 Million	₩2.40 Billion ≈ $1.63 Million	0.755x	--

About IBKS No2 SPAC

KQ:204840 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$44.15 Million

₩65.14 Billion KRW

Market Cap Rank

#22425 Global

#1456 in Korea

Share Price

₩4200.00

Change (1 day)

+1.45%

52-Week Range

₩780.00 - ₩5780.00

All Time High

₩8655.23